# GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT

> **NCT05510505** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 100 (estimated)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** CD20 monoclonal antibody
- **DRUG:** ATG

## Key facts

- **NCT ID:** NCT05510505
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-30
- **Primary completion:** 2023-09
- **Final completion:** 2025-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05510505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05510505, "GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05510505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*